Antineoplastics
1
Reactions 1034 - 15 Jan 2005 S Antineoplastics Acute promyelocytic leukaemia in a child: case report An 8-year-old girl developed acute promyelocytic leukaemia (APL) following treatment with a doxorubicin-containing regimen for non-Hodgkin’s lymphoma. Over 3 years, the girl received a total antineoplastic dosage of doxorubicin 350 mg/m 2 , cyclophosphamide 11 542 mg/m 2 , vincristine 59 mg/m 2 , methotrexate 2622 mg/m 2 , asparaginase 31 500 IU/m 2 and mercaptopurine 23 890 mg/m 2 . She achieved complete remission and antineoplastic therapy was stopped. One month later, she developed a haemorrhagic diathesis due to disseminated intravascular coagulation. She had a WBC count of 2500/µL with 13% blasts, a haemoglobin level of 11.6 g/dL, a platelet count of 76 000/µL and abnormal coagulation profiles. Following analysis of her bone marrow cells, she was diagnosed with therapy-related APL. The girl was treated with pirarubicin, cytarabine and tretinoin and achieved complete remission. She then received two courses of mitoxantrone, cytarabine and tretinoin, followed by a bone marrow transplant. Eleven months post- transplant, she remained in complete remission. Author comment: "We suspect that doxorubicin, probably linked with topoisomerase II inhibition, was responsible for the development of [therapy-related] APL." Ogami A, et al. Secondary acute promyelocytic leukemia following chemotherapy for non-Hodgkin’s lymphoma in a child. Journal of Pediatric Hematology/ Oncology 26: 427-430, No. 7, Jul 2004 - Japan 807217855 1 Reactions 15 Jan 2005 No. 1034 0114-9954/10/1034-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1034 - 15 Jan 2005
SAntineoplastics
Acute promyelocytic leukaemia in a child: casereport
An 8-year-old girl developed acute promyelocytic leukaemia(APL) following treatment with a doxorubicin-containingregimen for non-Hodgkin’s lymphoma.
Over 3 years, the girl received a total antineoplastic dosageof doxorubicin 350 mg/m2, cyclophosphamide 11 542 mg/m2,vincristine 59 mg/m2, methotrexate 2622 mg/m2, asparaginase31 500 IU/m2 and mercaptopurine 23 890 mg/m2. Sheachieved complete remission and antineoplastic therapy wasstopped. One month later, she developed a haemorrhagicdiathesis due to disseminated intravascular coagulation. Shehad a WBC count of 2500/µL with 13% blasts, a haemoglobinlevel of 11.6 g/dL, a platelet count of 76 000/µL and abnormalcoagulation profiles. Following analysis of her bone marrowcells, she was diagnosed with therapy-related APL.
The girl was treated with pirarubicin, cytarabine andtretinoin and achieved complete remission. She then receivedtwo courses of mitoxantrone, cytarabine and tretinoin,followed by a bone marrow transplant. Eleven months post-transplant, she remained in complete remission.
Author comment: "We suspect that doxorubicin, probablylinked with topoisomerase II inhibition, was responsible forthe development of [therapy-related] APL."Ogami A, et al. Secondary acute promyelocytic leukemia following chemotherapyfor non-Hodgkin’s lymphoma in a child. Journal of Pediatric Hematology/Oncology 26: 427-430, No. 7, Jul 2004 - Japan 807217855
1
Reactions 15 Jan 2005 No. 10340114-9954/10/1034-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
